Compare Abbott India with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs GLENMARK PHARMA - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA GLENMARK PHARMA ABBOTT INDIA/
GLENMARK PHARMA
 
P/E (TTM) x 59.6 15.6 383.3% View Chart
P/BV x 17.7 2.0 887.4% View Chart
Dividend Yield % 0.4 0.5 77.0%  

Financials

 ABBOTT INDIA   GLENMARK PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-19
GLENMARK PHARMA
Mar-19
ABBOTT INDIA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs8,834712 1,241.4%   
Low Rs5,458484 1,128.5%   
Sales per share (Unadj.) Rs1,731.1349.6 495.1%  
Earnings per share (Unadj.) Rs211.932.8 646.5%  
Cash flow per share (Unadj.) Rs219.944.3 496.0%  
Dividends per share (Unadj.) Rs65.002.00 3,250.0%  
Dividend yield (eoy) %0.90.3 271.8%  
Book value per share (Unadj.) Rs945.2198.6 475.8%  
Shares outstanding (eoy) m21.25282.17 7.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.11.7 241.5%   
Avg P/E ratio x33.718.2 185.0%  
P/CF ratio (eoy) x32.513.5 241.1%  
Price / Book Value ratio x7.63.0 251.3%  
Dividend payout %30.76.1 502.7%   
Avg Mkt Cap Rs m151,848168,625 90.1%   
No. of employees `0003.512.0 29.0%   
Total wages/salary Rs m4,35620,561 21.2%   
Avg. sales/employee Rs Th10,555.58,196.0 128.8%   
Avg. wages/employee Rs Th1,249.91,708.1 73.2%   
Avg. net profit/employee Rs Th1,292.2768.5 168.2%   
INCOME DATA
Net Sales Rs m36,78698,655 37.3%  
Other income Rs m1,1332,081 54.4%   
Total revenues Rs m37,919100,736 37.6%   
Gross profit Rs m6,04715,858 38.1%  
Depreciation Rs m1693,259 5.2%   
Interest Rs m233,346 0.7%   
Profit before tax Rs m6,98911,335 61.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m2,4853,756 66.2%   
Profit after tax Rs m4,5039,250 48.7%  
Gross profit margin %16.416.1 102.3%  
Effective tax rate %35.633.1 107.3%   
Net profit margin %12.29.4 130.6%  
BALANCE SHEET DATA
Current assets Rs m27,61066,968 41.2%   
Current liabilities Rs m8,56940,211 21.3%   
Net working cap to sales %51.827.1 190.8%  
Current ratio x3.21.7 193.5%  
Inventory Days Days6083 72.3%  
Debtors Days Days2781 33.7%  
Net fixed assets Rs m1,05733,322 3.2%   
Share capital Rs m213282 75.3%   
"Free" reserves Rs m19,87355,770 35.6%   
Net worth Rs m20,08656,052 35.8%   
Long term debt Rs m035,738 0.0%   
Total assets Rs m29,409132,888 22.1%  
Interest coverage x311.64.4 7,101.9%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.30.7 168.5%   
Return on assets %15.49.5 162.4%  
Return on equity %22.416.5 135.9%  
Return on capital %34.917.8 195.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36962,998 0.6%   
Fx outflow Rs m4,91822,859 21.5%   
Net fx Rs m-4,54940,140 -11.3%   
CASH FLOW
From Operations Rs m4,99113,242 37.7%  
From Investments Rs m-2,570-6,990 36.8%  
From Financial Activity Rs m-1,428-7,387 19.3%  
Net Cashflow Rs m993-2,971 -33.4%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 6.9 114.5%  
FIIs % 0.1 34.4 0.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 10.5 162.9%  
Shareholders   18,270 56,727 32.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   STERLING BIOTECH  PFIZER  ALEMBIC PHARMA  ORCHID PHARMA LTD  SANOFI INDIA  

Compare ABBOTT INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 129 Points Lower; Banking and Finance Stocks Witness Selling(Closing)

Indian share markets witnessed volatile trading activity throughout the day and ended their trading session marginally lower.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

6 Charts Showing the State of Indian Financial Markets in 2020(Sector Info)

May 26, 2020

Six charts showing how Indian financial markets have performed in 2020 so far...

Why We Picked This Smallcap Stock for a Post Coronavirus World(Profit Hunter)

May 28, 2020

Covid-19 has made it a survival of the fittest race for many companies. The ones that can adapt will thrive in a post crisis world.

What the RBI's Rate Cut Means for Options Traders(Fast Profits Daily)

May 25, 2020

The RBI governor has cut the repo rate to 4%. What does this mean for options traders? Find out in this video.

Who Will Be Crowned the 'Multibagger Blue Chip' of the Decade?(Profit Hunter)

May 25, 2020

Will the mutlibagger blue chips of the past decade continue to rule the bourses?

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Jun 4, 2020 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - JUBILANT LIFE SCIENCES COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS